Morgan Stanley cuts Alnylam price target to $240 from $300
Morgan Stanley lowered its price target on Alnylam Pharmaceuticals shares to $240 while keeping an equal-weight rating. Dow Jones Newswires reported the change, citing Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley reduced its price target on Alnylam Pharmaceuticals shares to $240 from $300. The bank kept its equal-weight rating, which signals a neutral stance. Dow Jones Newswires reported the change, citing data from Benzinga.
why it matters
A price target revision with an unchanged rating is a routine analyst action. It reflects one brokerage's updated valuation of the stock and usually does not shift the broader biotech sector or major indexes.
tags
instruments
sources
- Alnylam Pharmaceuticals Price Target Cut to $240.00/Share From $300.00 by Morgan Stanley — Dow Jones Newswires, 30 October 2026 at 17:48 UTC
- Amazon Price Target Cut to $335.00/Share From $350.00 by Morgan Stanley — Dow Jones Newswires, 30 October 2026 at 17:52 UTC
- Caterpillar Price Target Cut to $675.00/Share From $915.00 by Morgan Stanley — Dow Jones Newswires, 30 October 2026 at 18:04 UTC
- Alnylam Pharmaceuticals Price Target Cut to $199.00/Share From $376.00 by Bernstein — Dow Jones Newswires, 30 October 2026 at 18:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗